Is the intra-aortic balloon pump leaking?

摘要

Combined invasive and pharmacological treatment strategies have improved outcomes in acute myocardial infarction (Ml) substantially. However, mortality in cardiogenic shock, which occurs in about 7% of patients admitted with acute Ml, continues to be associated with high mortality (40-50%).* Yet trials in the emergency setting of acute Ml complicated by cardiogenic shock are exceptionally difficult to conduct. Therefore, Holger Thiele and colleagues should be commended for the rigorous IABP-SHOCK II trial, which is the largest trial in this setting to date. In The Lancet, Thiele and colleagues report the 12 month follow-up.